BioAegis Therapeutics: Funding, Investors & Team (Sep 2026)
BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
BioAegis Therapeutics has raised $22.0M across 1 funding round on record, the most recent an undisclosed round of $22.0M announced in Mar 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioAegis Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2022.
BioAegis Therapeutics Funding Rounds
BioAegis Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
BioAegis Therapeutics Funding Compared to Other Biotechnology Startups
BioAegis Therapeutics' latest round of $22.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioAegis Therapeutics in Biotechnology and Morristown
Companies Similar to BioAegis Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
BioAegis Therapeutics Funding FAQs
What does BioAegis Therapeutics do?
BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
How much funding has BioAegis Therapeutics raised?
BioAegis Therapeutics has raised $22.0M across 1 round on record. The most recent is an undisclosed round of $22.0M announced in Mar 2022.
When did BioAegis Therapeutics last raise funding?
BioAegis Therapeutics' most recent funding round on record is an undisclosed round of $22.0M, announced in Mar 2022.
Who is the CEO of BioAegis Therapeutics?
Susan Levinson is listed as CEO at BioAegis Therapeutics.
Where is BioAegis Therapeutics headquartered?
BioAegis Therapeutics is based in Morristown, New Jersey, United States.
How many employees does BioAegis Therapeutics have?
BioAegis Therapeutics is in the 11-50 employee band.
How does BioAegis Therapeutics' funding compare to other Biotechnology startups?
BioAegis Therapeutics' latest round of $22.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's BioAegis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioAegis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.